Bictegravir/Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir Plus Lamivudine for Switch Therapy in Patients with HIV-1 Infection: A Real-World Cohort Study-Reference-Cited by-同舟云学术

Bictegravir/Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir Plus Lamivudine for Switch Therapy in Patients with HIV-1 Infection: A Real-World Cohort Study

Published:2023-10-16 Issue:11 Volume:12 Page:2581-2593
ISSN:2193-8229
Container-title:Infectious Diseases and Therapy
language:en
Short-container-title:Infect Dis Ther

Author:

Gan Lin,Xie Xiaoxin,Fu Yanhua,Yang Xiaoyan,Ma Shujing,Kong Linghong,Song Chunli,Song Yebing,Ren Tingting,Long Hai^ORCID

Funder

Science and Technology Foundation of Guizhou

Publisher

Springer Science and Business Media LLC

Subject

Infectious Diseases,Microbiology (medical)

Link

https://link.springer.com/content/pdf/10.1007/s40121-023-00879-x.pdf

Reference29 articles.

1. Chen LY, Sun HY, Chuang YC, et al. Patient-reported outcomes in virally suppressed people living with HIV after switching to co-formulated bictegravir, emtricitabine and tenofovir alafenamide. J Microbiol Immunol Infect. 2023;56:575–85. https://doi.org/10.1016/j.jmii.2023.01.015.

2. Patel R, Evitt L, Mariolis I, et al. HIV treatment with the two-drug regimen of dolutegravir plus lamivudine in real-world clinical practice: a systematic literature review. Infect Dis Ther. 2021;10:2051–70. https://doi.org/10.1007/s40121-021-00522-7.

3. Trujillo-Rodríguez M, Muñoz-Muela E, Serna-Gallego A, et al. Immunological and inflammatory changes after simplifying to dual therapy in virologically suppressed HIV-infected patients through week 96 in a randomized trial. Clin Microbiol Infect. 2022;28:1151.e9–1151.e16. https://doi.org/10.1016/j.cmi.2022.02.041.

4. da Cunha J, Maselli LMF, Stern ACB, Spada C, Bydlowski SP. Impact of antiretroviral therapy on lipid metabolism of human immunodeficiency virus-infected patients: old and new drugs. World J Virol. 2015;4:56–77. https://doi.org/10.5501/wjv.v4.i2.56.

5. Kumar S, Samaras K. The impact of weight gain during HIV treatment on risk of pre-diabetes, diabetes mellitus, cardiovascular disease, and mortality. Front Endocrinol. 2018;9:705. https://doi.org/10.3389/fendo.2018.00705.

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Characteristics and real-world medication persistence of people living with HIV treated with DTG/3TC or BIC/FTC/TAF: a hospital claims database study in Japan;Frontiers in Medicine;2024-09-10

2. Effectiveness, safety and discontinuation rates of bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) in people with HIV using real-world data: a systematic review and meta-analysis;Journal of Antimicrobial Chemotherapy;2024-05-17

3. Dolutegravir/Lamivudine versus Tenofovir Alafenamide/Emtricitabine/Bictegravir as a Switch Strategy in a Real-Life Cohort of Virogically Suppressed People Living with HIV;Journal of Clinical Medicine;2023-12-18